ProImmune has launched the Reveal B Cell Epitope Discovery System, a service designed to accelerate the development of biological therapies and understanding of diseases at a structural level.
The Reveal service offers best consensus epitope prediction and rapid high-throughput linear epitope mapping in vitro.
Reveal consensus epitope prediction is a key tool in developing incisive hypotheses for downstream in vitro research.
The service is based not only on primary sequence and 3D structure, but also incorporates any other additional information about the protein of interest from publicly available sources, and the experience and knowledge of ProImmune's team to provide an intelligent consensus prediction to identify potential epitopes in a protein of interest.
Unlike hard-to-control assays that rely on recombinant or purified proteins, Reveal linear epitope mapping relies on standardised peptide synthesis, which simplifies and accelerates the measurement of large numbers of samples.
Based on Pro-array high-content peptide microarrays that can include thousands of peptides, the service provides a turnkey solution for applications such as vaccine subunit discovery, immunogenicity testing, and correlating antibody responses to protein targets with disease onset, progression and outcome.
